Weibel R E, Buynak E B, McLean A A, Hilleman M R
Pediatrics. 1978 Jan;61(1):5-11.
Hemagglutination-inhibiting antibodies were retained in comparable levels eight years after vaccination with Enders' original Edmonston and more attenuated Moraten (Attenuvax) and Schwarz line measles vaccines. Neutralizing antibody persisted without substantial decline in titer for at least 9.5 years after administration of Jeryl Lynn mumps virus vaccine (Mumpsvax). Antibodies were retained without important decline in children and adults for at least 7.5 and 7 years, respectively, after administration of HPV-77 duck-modified rubella vaccine (Meruvax). The patterns of antibody persistence 7.5 years after administration of combined measles-mumps-rubella (M-M-R) and mumps-rubella (Biavax) vaccines, 6 years after administration of measles-rubella vaccine (M-R-VAX), and 4 years after administration of measles-mumps vaccine (M-M-VAX) were the same as for the monovalent vaccines, indicating no alteration in the retention of immunity. Subclinical reinfection evidenced by increase in homologous antibody titer was observed to follow vaccination the same as occurs after natural infection.
接种恩德斯原始的埃德蒙斯顿疫苗以及减毒程度更高的莫拉坦（Attenuvax）和施瓦茨株麻疹疫苗八年后，血凝抑制抗体水平仍处于可比状态。接种杰里尔·林恩腮腺炎病毒疫苗（Mumpsvax）后，中和抗体至少在9.5年内持续存在且滴度无显著下降。接种HPV - 77鸭源减毒风疹疫苗（Meruvax）后，儿童和成人的抗体至少分别在7.5年和7年内持续存在且无显著下降。接种麻疹 - 腮腺炎 - 风疹联合疫苗（M - M - R）和腮腺炎 - 风疹疫苗（Biavax）7.5年后、接种麻疹 - 风疹疫苗（M - R - VAX）6年后以及接种麻疹 - 腮腺炎疫苗（M - M - VAX）4年后的抗体持续模式与单价疫苗相同，表明免疫保留情况未发生改变。与自然感染后情况相同，接种疫苗后观察到同源抗体滴度升高证明存在亚临床再感染。
